Argus Upgrades Teva Pharma (TEVA) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $40.72 -1.28%
Rating Summary:
20 Buy, 19 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 59
Rating Summary:
20 Buy, 19 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 59
Join SI Premium – FREE
Argus upgraded Teva Pharma (NYSE: TEVA) from Hold to Buy with a price target of $58.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $50.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) PT Raised to $52 at Oppenheimer
- JPMorgan Upgrades Paladin Energy (PDN:AU) (PALAF) to Overweight
- JPMorgan Upgrades Mingyang Smart Energy (601615:CH) to Neutral
Create E-mail Alert Related Categories
UpgradesRelated Entities
ArgusSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
